

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Foster-Cheek Kaye I</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>10/19/2022</u>		3. Issuer Name and Ticker or Trading Symbol <u>Prime Medicine, Inc. [PRME]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director Officer (give title below)			5. If Amendment, Date of Original Filed (Month/Day/Year)	
C/O PRIME MEDICINE, INC. 21 ERIE STREET			10% Owner			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	
(Street)	(City)	(State)	(Zip)				
CAMBRIDGE	MA	02139					

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (right to buy)</u>	<u>(I)</u>	<u>01/24/2032</u>	<u>Common Stock</u>	<u>13,510</u>	<u>10.92</u>	<u>D</u>	

Explanation of Responses:

1. The shares underlying this option shall vest in three equal annual installments following December 23, 2021, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Carman Alenson attorney-in-fact

10/19/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Keith Gottesdiener, Carman Alenson and Karen Brown of Prime Medicine, Inc., a Delaware

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, from time

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any

(3) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act a

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of
October 19, 2022.

/s/ Kaye Foster-Cheek
Signature

Kaye Foster-Cheek
Print Name